[1]
|
Sofie, N., Karoline, K. and Veronika, S. (2020) The Role of CDK6 in Cancer. International Journal of Cancer, 147, 2988-2995. https://doi.org/10.1002/ijc.33054
|
[2]
|
Harbour, J.W., Luo, R.X., Dei Santi, A., et al. (1999) CDK Phosphorylation Triggers Sequential Intramolecular Interactions That Progressively Block Rb Functions as Cells Move through G1. Cell, 98, 859-869.
https://doi.org/10.1016/S0092-8674(00)81519-6
|
[3]
|
Johnson, N. and Geoffrey, I.S. (2012) Cyclin-Dependent Kinase 4/6 Inhibition in Cancer Therapy. Cell Cycle, 11, 3913-3913. https://doi.org/10.4161/cc.22390
|
[4]
|
Anne, F., Yan, G. and Piotr, S. (2022) CDK4 and CDK6 Kinases: From Basic Science to Cancer Therapy. Science, 375, eabc1495. https://doi.org/10.1126/science.abc1495
|
[5]
|
Johannes, E. (2019) Management of Adverse Events Due to Cy-clin-Dependent Kinase 4/6 Inhibitors. Breast Care (Basel), 14, 86-92. https://doi.org/10.1159/000499534
|
[6]
|
Hortobagyi, G.N., Stemmer, S.M., Burris, H.A., et al. (2022) Overall Sur-vival with Ribociclib plus Letrozole in Advanced Breast Cancer. The New England Journal of Medicine, 386, 942-950. https://doi.org/10.1056/NEJMoa2114663
|
[7]
|
Dickson, M.A., Schwartz, G.K., et al. (2016) Progression-Free Survival among Patients with Well-Differentiated or Dedifferentiated Liposarcoma Treated with CDK4 Inhibitor Palbo-ciclib: A Phase 2 Clinical Trial. JAMA Oncology, 2, 937-940. https://doi.org/10.1001/jamaoncol.2016.0264
|
[8]
|
Assi, T., Kattan, J., Rassy, E., et al. (2020) Targeting CDK4 (Cyclin-Dependent Kinase) Amplification in Liposarcoma: A Comprehensive Review. Critical Reviews in Oncolo-gy/Hematology, 153, Article ID: 103029.
https://doi.org/10.1016/j.critrevonc.2020.103029
|
[9]
|
Crozier, L., Foy, R., Mouery, B.L., et al. (2022) CDK4/6 In-hibitors Induce Replication Stress to Cause Long-Term Cell Cycle Withdrawal. EMBO Journal, 41, e108599. https://doi.org/10.15252/embj.2021108599
|
[10]
|
Tong, J.S., Tan, X., Song, X.P., et al. (2022) CDK4/6 Inhibition Suppresses p73 Phosphorylation and Activates DR5 to Potentiate Chemotherapy and Immune Checkpoint Blockade. Cancer Research, 82, 1340-1352.
https://doi.org/10.1158/0008-5472.CAN-21-3062
|
[11]
|
Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Can-cer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249.
https://doi.org/10.3322/caac.21660
|
[12]
|
Qian, Y., Wu, X., Wang, H.X., et al. (2020) PAK1 Silencing Is Synthetic Lethal with CDK4/6 Inhibition in Gastric Cancer Cells via Regulating PDK1 Expression. Human Cell, 33, 377-385. https://doi.org/10.1007/s13577-019-00317-6
|
[13]
|
Bae, H.J., Kang, S.K., Kwon, W.S., et al. (2021) p16 Methyla-tion Is a Potential Predictive Marker for Abemaciclib Sensitivity in Gastric Cancer. Biochemical Pharmacology, 183, Ar-ticle ID: 114320.
https://doi.org/10.1016/j.bcp.2020.114320
|
[14]
|
Chen, Z.H., Xu, Y.Y., Gong, J.F., et al. (2020) Pyrotinib Com-bined with CDK4/6 Inhibitor in HER2-Positive Metastatic Gastric Cancer: A Promising Strategy from AVATAR Mouse to Patients. Clinical and Translational Medicine, 10, e148. https://doi.org/10.1002/ctm2.148
|
[15]
|
Bi, H.T., Shang, J., Zou, X., et al. (2021) Palbociclib Induces Cell Senescence and Apoptosis of Gastric Cancer Cells by Inhibiting the Notch Pathway. Oncology Letters, 22, 603. https://doi.org/10.3892/ol.2021.12864
|
[16]
|
Min, A., Kim, J.E., Kim, Y.-J., et al. (2018) Cyclin E Overexpression Confers Resistance to the CDK4/6 Specific Inhibitor Palbociclib in Gastric Cancer Cells. Cancer Letters, 430, 123-132. https://doi.org/10.1016/j.canlet.2018.04.037
|
[17]
|
Chen, L., et al. (2017) Dual Cyclin-Dependent Kinase 4/6 Inhibition by PD-0332991 Induces Apoptosis and Senescence in Oesophageal Squamous Cell Carcinoma Cells. British Journal of Pharmacology, 174, 2427-2443.
https://doi.org/10.1111/bph.13836
|
[18]
|
Wang, J.Y., Li, Q.Q., Yuan, J.J., et al. (2017) CDK4/6 Inhibitor-SHR6390 Exerts Potent Antitumor Activity in Esophageal Squamous Cell Carcinoma by Inhibiting Phosphorylated Rb and Induc-ing G1 Cell Cycle Arrest. Journal of Translational Medicine, 15, 127. https://doi.org/10.1186/s12967-017-1231-7
|
[19]
|
Karasic, T.B., O’Hara, M.H., Teitelbaum, U.R., et al. (2020) Phase II Trial of Palbociclib in Patients with Advanced Esophageal or Gastric Cancer. Oncologist, 25, e1864-e1868. https://doi.org/10.1634/theoncologist.2020-0681
|
[20]
|
Zheng R., Zhang, S., Zeng, H., et al. (2022) Cancer Incidence and Mortality in China, 2016. Journal of the National Cancer Center, 2, 1-9. https://doi.org/10.1016/j.jncc.2022.02.002
|
[21]
|
Thoma, O.M., Neurath, M.F. and Waldner, M.J. (2021) Cy-clin-Dependent Kinase Inhibitors and Their Therapeutic Potential in Colorectal Cancer Treatment. Frontiers in Pharma-cology, 12, Article ID: 757120.
https://doi.org/10.3389/fphar.2021.757120
|
[22]
|
Lee, M.S., Helms, T.L., Feng, N.P., et al. (2016) Efficacy of the Combination of MEK and CDK4/6 Inhibitors in Vitro and in Vivo in KRAS Mutant Colorectal Cancer Models. Oncotar-get, 7, 39595-39608.
https://doi.org/10.18632/oncotarget.9153
|
[23]
|
Chen, S.-H., Gong, X., Zhang, Y., et al. (2018) RAF Inhibitor LY3009120 Sensitizes RAS or BRAF Mutant Cancer to CDK4/6 Inhibition by Abemaciclib via Superior Inhibition of Phospho-RB and Suppression of Cyclin D1. Oncogene, 37, 821-832. https://doi.org/10.1038/onc.2017.384
|
[24]
|
Wang, Y.N., Liao, H.Y., Zheng, T.S., et al. (2020) Conditionally Re-programmed Colorectal Cancer Cells Combined with Mouse Avatars Identify Synergy between EGFR and MEK or CDK4/6 Inhibitors. American Journal of Cancer Research, 10, 249-262.
|
[25]
|
Piro, G., Carbone, C., Santoro, R., et al. (2018) Predictive Biomarkers for the Treatment of Resectable Esophageal and Esophago-Gastric Junction Adenocarci-noma: From Hypothesis Generation to Clinical Validation. Expert Review of Molecular Diagnostics, 18, 357-370. https://doi.org/10.1080/14737159.2018.1454312
|